Post by Cirrus Therapeutics

The 2026 Breakthrough Prize in Life Sciences recognizes more than a landmark achievement. It celebrates discovery that has changed the trajectory of the entire field. This year’s award honors Jean Bennett, MD, PhD; Albert Maguire,MD; and Katherine High, MD. Their work led to Luxturna, the first FDA-approved gene therapy for an inherited disease, restoring sight for people with a form of inherited blindness and helping establish the clinical, regulatory, and manufacturing foundation for modern retinal gene therapy. For many working in vision science today, that legacy is not abstract. Luxturna did more than restore sight for patients with a rare retinal disease. It helped prove that ocular gene therapy could work safely, durably, and meaningfully in humans. It opened the door for the many retinal gene therapy programs that have followed. “As someone who has spent decades in ocular drug development and retinal gene therapy, I see this recognition as both a celebration and a call to action for the field,” said Meihua Ju, PhD, Vice President of Translational Research at Cirrus Therapeutics. “The success of Luxturna proved that gene therapy could restore meaningful vision and created a path forward for the rest of us. Our responsibility now is to build on that foundation and extend the promise of gene therapy to broader retinal diseases, including dry AMD, where patients continue to face significant unmet needs.” Cirrus is proud to be part of the next chapter, advancing a differentiated IRAK-M–targeted ocular gene therapy designed to address an underlying driver of dry AMD and help preserve central vision as people age. Congratulations to this year’s laureates for helping redefine what is possible in blindness research and for moving the entire field forward. #vision #AMD #DryAMD #WetAMD #optometry #opthalmology #healthcare #science #STEM #biotech #biopharma #research #lifesciences #breakthroughprize #womeninscience #leadership Breakthrough Prize Foundation